ArticleInternational journal of clinical oncology2026
CD8/CD4 ratio, CD56, and PD-L1 as prognostic markers in sinonasal mucosal melanoma.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSinonasal mucosal melanoma (SNMM) is an aggressive malignancy with limited prognostic markers. This study aimed to determine whether immune markers, including the CD8 to CD4 lymphocyte ratio, CD56-positive lymphocytes, and PD-L1 expression, provide prognostic information beyond established clinicopathological factors.
methodsWe retrospectively reviewed 67 patients with surgically treated SNMM at two tertiary medical centers in Taiwan between 2004 and 2023. Standard histopathologic parameters and immunohistochemical assessments of the CD8/CD4 ratio, CD56-positive lymphocytes, and PD-L1 expression in tumor and stromal immune cells were evaluated. Disease-specific survival (DSS) and recurrence-free survival (RFS) were analyzed using Kaplan-Meier estimates and multivariable Cox proportional hazards models.
resultsThe median patient age was 62 years, and 60% were male. During a median follow-up of 42 months, 63% of patients experienced recurrence, and 54% died of the disease. An increased CD8/CD4 ratio and the presence of CD56-positive lymphocytes were associated with better DSS (5-year DSS, 64.3% vs. 32.1% and 70.1% vs. 35.8%, respectively), whereas PD-L1 positivity was associated with shorter RFS (5-year RFS, 28.6% vs. 54.3%). In multivariable analysis, mitotic activity of ≥ 10/mm
conclusionsImmune markers, particularly the CD8/CD4 ratio and CD56-positive lymphocytes, were significantly associated with survival outcomes independent of traditional histopathologic factors. Incorporating immune profiling into risk stratification may improve prognostication and guide the development of immune-targeted strategies in SNMM.
Indexed as
Identifiers
41620992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.